Plutavimab

DB18856InvestigationalProtein Based Therapies

Plutavimab is under investigation in clinical trial NCT04900428 (Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)).

Mechanism: Pharmacologically active on Spike glycoprotein
Curator reviewed
Also known as: Affinity matured covi-guard · Covi-amg · Covi-drops · Immunoglobulin g1 (234-alanine,235-alanine), anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding domain) (human monoclonal sti-2020 .gamma.1-chain), disulfide with human monoclonal sti-2020 .kappa.-chain, dimer
Code names: STI-2020 · STI-2099

Resolves to

Compound

UNII12U14K0SR5CAS2529854-88-2

Targets

P0DTC2S

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Plutavimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account